Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Aqueous Two-Phase Systems Enable Homogeneous Immunoassay Multiplexing

By LabMedica International staff writers
Posted on 28 Jul 2014
A novel test simplifies disease detection by enabling simultaneous detection of multiple proteins in blood plasma in only two hours.

The test can accurately and simultaneously measure multiple biomarker proteins that indicate the presence of diseases like graft-versus-host disease as happens in bone marrow transplant rejection and needs no washing steps, and uses only a minute volume of blood plasma.

Scientists at the University of Michigan (Ann Arbor, MI, USA) developed the protein test, which uses a micropatterning method. More...
To perform the assay, a few microliters of blood plasma is mixed with poly(ethylene glycol) and added to a microwell in a custom 384-well microplate. Next, microdroplets of dextran, containing complimentary pairs of antibody-beads, are dispensed into microbasins within the sample well. During two-hour incubation, target plasma protein biomarkers diffuse from the poly(ethylene glycol) phase to the dextran droplets and become sandwiched by the antibody beads. The microplate is then read on a commercially available plate reader.

The cross-reaction-free, multiplex assay can simultaneously detect picomolar concentrations of four protein biomarkers: C-X-C motif ligand 10 (CXCL10), CXCL9, interleukin (IL)-8 and IL-6 in cell supernatants using a single assay well. The potential clinical utility of the assay was demonstrated by detecting diagnostic biomarkers (CXCL10 and CXCL9) in plasma from 88 patients at the onset of the clinical symptoms of chronic graft-versus-host disease (GVHD).

Shuichi Takayama, PhD, a professor and a senior author of the study, said, “Just as oil and water remain immiscible, we use two aqueous solutions that do not mix with each other. Interestingly, these solutions can be patterned into arrays, whereas standard no-wash protein test reagents normally just mix together in solution. This novel capability makes it possible, for the first time, to measure multiple diagnostic proteins at a time in a no-wash format test.”

Arlyne Simon, PhD, the lead author of the study, said, “We envision that our user-friendly and highly accurate platform will be widely used by academic and clinical scientists for diagnostics as well as other applications. To ease the adoption of our technology into research and clinical labs, we designed custom microplates that can be analyzed by commercially available plate readers.” The study was published on June 2, 2014, in the journal TECHNOLOGY.

Related Links:

University of Michigan



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Automated Urinalysis Solution
UN-9000
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.